SeqOne Genomics, a Montpellier, France-based provider of next genomic analysis solutions for personalized medicine, raised €20M in Series A funding.
The round was led by Omnes, Merieux Equity Partners, with participation from the Software Club and existing investors, Elaia and IRDI Capital Investissement.
The company intends to use the funds to accelerate its international sales and the development of new collaborative genomic analysis tools to facilitate communications between different disciplines in the medical team, in order to improve patient outcomes in cancer and hereditary disease.
Led by Nicolas Philippe, Ph.D., Co-founder and CEO, SeqOne Genomics provides a cloud-based solution that manages the entire genomic analysis process from raw data to final report presented to clinicians. The company offers high performance genomic analysis solutions for healthcare providers treating patients suffering from cancer, rare and hereditary diseases as well as pharmaceutical companies developing new therapies. The solution leverages advanced machine learning coupled with the company’s proprietary GeniOS™ genomics operating system to reduce turnaround times and costs while delivering a comprehensive and actionable insights for personalised medicine.
With the closing of this round, SeqOne’s board of directors will be:
- Sacha Loiseau, Ph.D. independent board member and Chairman of the Board,
- Fabien Collangettes, Director at Omnes,
- Yoann Bonnamour, Investment Manager at Merieux Equity Partners,
- Marc Rougier, Partner at Elaia,
- Nicolas Philippe, co-founder and CEO of SeqOne Genomics, and
- Jean-Marc Holder, Co-founder and Chief Strategy and Innovation officer of SeqOne Genomics.
The company currently employs over 40 staff, primarily experts in genomic medicine, data science, bioinformatics, software development and regulatory compliance / quality assurance.
FinSMEs
24/01/2022